Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the P...(ded the appointment of seasoned Business...)

Date:2/16/2009

ded the appointment of seasoned Business Development Managers in the US and Europe. Cooper's addition to the Copan leadership team, and the breakthrough technology behind the WASP, provide the ideal composition and opportunity for Copan to help laboratories in different parts of the world achieve efficiencies and productivity in microbiology specimen processing, where full automation had not previously existed.

About the Copan Group

With a reputation for innovation in preanalytics, the Copan Group, comprising of Copan Innovation Ltd., Copan Italia, S.p.A., Copan Diagnostics Inc. and MicroRheologics S.r.l., is the leading manufacturer and provider of collection and transport systems in the world. Copan offers a complete range of microbial sampling products used for traditional culture analysis and for molecular diagnostic assays, as well as producing innovations, like the patented Flocked Swabs, Universal Transport Medium and ESwab. The company manufactures a comprehensive line of laboratory consumables comprising of inoculation loops, needles, spreaders and transfer pipettes. Copan has recently launched WASP: Walk-Away Specimen Processor, a new revolutionary system for automatic planting and streaking of microbiology samples. For more information about Copan, visit www.copaninnovation.com

'/>"/>

SOURCE Copan Innovation Ltd. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2
Related biology technology :

1. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
2. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
7. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
8. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
9. Cord Blood Announces $1 Million Reduction in Long Term Debt
10. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
11. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors